Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings
The Second Week Of Earnings Season Took A Bad Turn
Executive Summary
Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.
You may also be interested in...
Lilly Tries To Keep Investors Focused On The Pipeline, Not Performance
With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.
Novartis Big Earners Beat Q1 Forecasts
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
Stock Watch: J&J And Roche Invite Comparison
Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?